Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: A randomized controlled trial

Sleep

Volumn 35, Issue 10, 2012, Pages 1395-1402

  Scheer, Frank A J L ^a,b   Morris, Christopher J ^a,b   Garcia, Joanna I ^a   Smales, Carolina ^a   Kelly, Erin E ^a   Marks, Jenny ^a   Malhotra, Atul ^a,b   Shea, Steven A ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Actigraphy; Adrenergic beta antagonists; Atenolol; Autonomic nervous system; Hypertension; Hypnotics; Melatonin; Metoprolol; Polysomnography; Sleep

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MELATONIN; METOPROLOL; PLACEBO; THIAZIDE DIURETIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MALE; POLYSOMNOGRAPHY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP; SLEEP PARAMETERS; SLEEP QUALITY; SLEEP STAGE; SLEEP TIME; TREATMENT OUTCOME;

ACTIGRAPHY; ADRENERGIC BETA-ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MELATONIN; MIDDLE AGED; POLYSOMNOGRAPHY; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84867055019     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.2122     Document Type: Article

References (50)

1. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. Hyattsville, MD: National Center for Health Statistics, 2010 Sep.
2. Brismar K, Hylander B, Eliasson K, Rössner S, Wetterberg L. Melatonin secretion related to side-effects of beta-blockers from the central nervous system. Acta Med Scand 1988;223:525-30.
3. Kostis JB, Rosen RC. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. Circulation 1987;75:204-12. (Pubitemid 17234559)
4. Kostis JB, Rosen RC, Holzer BC, Randolph C, Taska LS, Miller MH. CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males. Psychopharmacology (Berl) 1990;102:163-70. (Pubitemid 20264654)
5. Danchin N, Genton P, Atlas P, Anconina J, Leclere J, Cherrier F. Comparative effects of atenolol and clonidine on polygraphically recorded sleep in hypertensive men: a randomized, double-blind, crossover study. Int J Clin Pharmacol Ther 1995;33:52-5.
6. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. Jama 2002;288:351-7. (Pubitemid 34761614)
7. Cowen PJ, Bevan JS, Gosden B, Elliott SA. Treatment with beta-adrenoceptor blockers reduces plasma melatonin concentration. Br J Clin Pharmacol 1985;19:258-60. (Pubitemid 16216343)
8. Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985;60:1166-73. (Pubitemid 15064777)
9. Nathan PJ, Maguire KP, Burrows GD, Norman TR. The effect of atenolol, a beta1-adrenergic antagonist, on nocturnal plasma melatonin secretion: evidence for a dose-response relationship in humans. J Pineal Res 1997;23:131-5. (Pubitemid 127500004)
10. Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 1999;55:111-5. (Pubitemid 29196263)
11. Van Den Heuvel CJ, Reid KJ, Dawson D. Effect of atenolol on nocturnal sleep and temperature in young men: reversal by pharmacological doses of melatonin. Physiol Behav 1997;61:795-802. (Pubitemid 27237150)
12. Scheer FA, Czeisler CA. Melatonin, sleep, and circadian rhythms. Sleep Med Rev 2005;9:5-9. (Pubitemid 40092914)
13. Ayas NT, White DP, Manson JE, et al. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med 2003;163:205-9. (Pubitemid 36120188)
14. Gangwisch JE, Heymsfield SB, Boden-Albala B, et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension 2006;47:833-9. (Pubitemid 44297552)
15. Spiegel K, Tasali E, Leproult R, Van Cauter E. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat Rev Endocrinol 2009;5:253-61.
16. Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med 2004;1:e62.
17. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667-89.
18. Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol 1985;19:517-21. (Pubitemid 16254595)
19. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Bethesda, MD: US Department of Health, Education, and Welfare Public Health Service - NIH/NIND, 1968.
20. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 2001;323:1123-4. (Pubitemid 33063362)
21. Emilien G, Maloteaux JM. Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol 1998;53:389-404. (Pubitemid 28154739)
22. Zeitzer JM, Ayas NT, Shea SA, Brown R, Czeisler CA. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J Clin Endocrinol Metab 2000;85:2189-96. (Pubitemid 32269243)
23. Scheer FA, Zeitzer JM, Ayas NT, Brown R, Czeisler CA, Shea SA. Reduced sleep efficiency in cervical spinal cord injury; association with abolished night time melatonin secretion. Spinal Cord 2006;44:78-81. (Pubitemid 43190350)
24. Brugger P, Marktl W, Herold M. Impaired secretion of melatonin in coronary heart disease. Lancet 1995;345:1408.
25. Sakotnik A, Liebmann PM, Stoschitzky K, et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 1999;20:1314-7. (Pubitemid 29429717)
26. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003;12:19-24. (Pubitemid 36416949)
27. Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995;346:541-4.
28. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001;86:4727-30. (Pubitemid 33020512)
29. Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol Sci 1996;17:100-2. (Pubitemid 26111451)
30. Morris CJ, Aeschbach D, Scheer FA. Circadian system, sleep and endocrinology. Mol Cell Endocrinol 2012;349:91-104.
31. Burgess HJ, Revell VL, Eastman CI. A three pulse phase response curve to three milligrams of melatonin in humans. J Physiol 2008;586:639-47.
32. Liu C, Weaver DR, Jin X, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997;19:91-102. (Pubitemid 27332996)
33. Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. Activation of MT melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol 2001;280:C110-8. (Pubitemid 32523404)
34. Krauchi K, Cajochen C, Pache M, Flammer J, Wirz-Justice A. Thermoregulatory effects of melatonin in relation to sleepiness. Chronobiol Int 2006;23:475-84. (Pubitemid 43739058)
35. Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv 2005;56:332-43. (Pubitemid 40333567)
36. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007;22:1335-50. (Pubitemid 47247294)
37. Longo LP, Johnson B. Addiction: Part I. Benzodiazepines - side effects, abuse risk and alternatives. Am Fam Physician 2000;61:2121-8. (Pubitemid 30225617)
38. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 1999;14:287-303.
39. Aeschbach D, Dijk DJ, Trachsel L, Brunner DP, Borbely AA. Dynamics of slow-wave activity and spindle frequency activity in the human sleep EEG: effect of midazolam and zopiclone. Neuropsychopharmacology 1994;11:237-44. (Pubitemid 24372812)
40. Hoffman RS, Wipfler MG, Maddaloni MA, Weisman RS. Has the New York State triplicate benzodiazepine prescription regulation influenced sedative-hypnotic overdoses? N Y State J Med 1991;91:436-9.
41. Allain H, Bentue-Ferrer D, Tarral A, Gandon JM. Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol 2003;59:179-88. (Pubitemid 36995125)
42. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012;2:e000850.
43. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005;9:25-39. (Pubitemid 40092916)
44. Stoschitzky K, Stoschitzky G, Brussee H, Bonelli C, Dobnig H. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006;106:199-206. (Pubitemid 44763172)
45. Stoschitzky K, Koshucharova G, Lercher P, et al. Stereoselective effects of (R)- and (S)-carvedilol in humans. Chirality 2001;13:342-6. (Pubitemid 32550037)
46. Wyatt JK, Dijk DJ, Ritz-de Cecco A, Ronda JM, Czeisler CA. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 2006;29:609-18.
47. Rommel T, Demisch L. Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. J.Neural.Transm.[GenSect] 1994;95:39-48.
48. Paran E, Anson O, Neumann L. The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. Am J Hypertens 1996;9(12 Pt 1):1206-13. (Pubitemid 26423645)
49. Danjou P, Puech A, Warot D, Benoit JF. Lack of sleep-inducing properties of propranolol (80 mg) in chronic insomniacs previously treated by common hypnotic medications. Int Clin Psychopharmacol 1987;2:135-40.
50. Scheer FAJL, van Montfrans GA, Van Someren EJW, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004;43:192-7. (Pubitemid 38174173)